US Patent Issued to The Feinstein Institutes for Medical Research on Oct. 6 for "Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-19" (New York, New Jersey, Connecticut Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,417, issued on Oct. 6, was assigned to The Feinstein Institutes for Medical Research (Manhasset, N.Y.).

"Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-19" was invented by Haichao Wang (Edison, N.J.), Kevin J. Tracey (Old Greenwich, Conn.), Jian Hua Li (New York), Cassie Zhu (Great Neck, N.Y.) and Xiaoling Qiang (Hicksville, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies and fragments thereof, which inhibit the interaction between the spike protein RBM and human ACE2, as well as methods of use employing such antibodies an...